This article was originally published in The Gray Sheet
Expects to begin clinical trials of an in vitro blood test designed to measure the effectiveness of cancer treatment "in the first half of 1993," according to a recent press release. The test measures the level of human carcinoma antigen (HCA) in the bloodstream. A U.S. patent application was filed in February for the test and two other products: an in vivo imaging agent designed to identify a tumor site with a radioactive label and a cancer vaccine which "uses proprietary anti-idiotypic monoclonal antibodies to act like purified HCA and activate an immune system response to treat malignant tumors." Epigen plans to file an investigational new drug application for the imaging agent in the second quarter.
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.